Please ensure Javascript is enabled for purposes of website accessibility

Clovis Oncology Secures FDA Approval for Rubraca in Prostate Cancer

By Brian Orelli, PhD – May 16, 2020 at 11:31AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Rubraca is the first PARP inhibitor approved for prostate cancer.

On Friday, Clovis Oncology (CLVS -5.08%) gained Food and Drug Administration approval of Rubraca for patients with metastatic castration-resistant prostate tumors that have BRCA mutations.

Rubraca inhibits poly ADP-ribose polymerase (PARP) proteins that are involved in the repair of DNA. By itself, inhibition of PARP doesn't do much, but inhibiting the repair proteins in the presence of mutations in BRCA proteins, which are also responsible for repairing DNA, results in enough damage to cancer cells' DNA that the tumor cells ultimately die.

Doctor talking to a patient in an exam room

Image source: Getty Images.

In the pivotal clinical trial used to gain FDA approval, 44% of patients with BRCA prostate cancer responded to Rubraca, defined as a shrinking of the prostate tumor without progression of bone tumors. When looking at tumors via prostate specific antigen -- a measure of prostate cancer cells -- Rubraca produced a 55% response rate.

Rubraca is already approved for ovarian cancer, where the drug produced $42.6 million in sales during the first quarter of 2020. While the drug is far from a blockbuster, sales were up 8% quarter over quarter and 29% year over year, suggesting there's still some growth left in ovarian cancer as Clovis Oncology competes with PARP inhibitors GlaxoSmithKline's (GSK -2.17%) Zejula and AstraZeneca (AZN -3.07%) and Merck's (MRK -0.83%) Lynparza.

Prostate cancer offers additional upside for Clovis where 12% of men with metastatic castration-resistant prostate cancer have mutations in one of the BRCA genes, although many of those patients may end up being treated with Rubraca after the use of traditional chemotherapy agents.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Clovis Oncology, Inc. Stock Quote
Clovis Oncology, Inc.
CLVS
$1.12 (-5.08%) $0.06
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$86.78 (-0.83%) $0.73
GSK Stock Quote
GSK
GSK
$29.36 (-2.17%) $0.65
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$54.58 (-3.07%) $-1.73

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.